Posts

FDA Approves Bizengri (Zenocutuzumab) for NRG1 Fusion-Positive Cholangiocarcinoma, First Targeted Therapy for Ultra-Rare Bile Duct Cancer

on

Boehringer Ingelheim's Hernexeos Receives Speedy FDA Approval for Lung Cancer Under CNPV Program

on

FDA Rejects Disc Medicine's Bitopertin for Rare Blood Disorder EPP Despite Commissioner's Priority Voucher

on

J&J's Tecvayli and Darzalex Combo Wins FDA's Proactive National Priority Voucher for Relapsed/Refractory Multiple Myeloma

on

FDA's Pazdur Raises Concerns Over Legality of National Priority Voucher Program Amid Internal Disagreement

on

FDA Announces First Recipients of Makary’s National Priority Voucher Program, Expanding Scope for Accelerated Drug Reviews

on

FDA Launches New Priority Review Voucher Program Aligned with National Priorities

on